Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer

Authors: Tsui Fen Cheng, Jung Der Wang, Wu Ching Uen

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Increased health care costs have made it incumbent on health-care facilities and physicians to demonstrate both clinical and cost efficacy when recommending treatments. Though studies have examined the cost-effectiveness of adjuvant goserelin with radiotherapy for locally advanced prostate cancer, few have compared the cost-effectiveness of adjuvant goserelin to adjuvant chemotherapy alone in premenopausal breast cancer.

Methods

In this retrospective study at one hospital, the records of 152 patients with stage Ia to IIIa ER + breast cancer who received goserelin or chemotherapy were reviewed. Survival analysis was assessed by the Kaplan-Meier method. Patients were interviewed to evaluate their quality of life using the European Organization for Research and Treatment Quality of Life questionnaire (EORTC-QLQ-C30, version 4.0), and to obtain the utility value by the standard gamble (SG) and visual scale (VS) methods. Total medical cost was assessed from the (National Health Insurance) NHI payer's perspective.

Results

Survival at 11 years was significantly better in the groserelin group (P < 0.0012). The lifetime lost was lower in the goserelin group (42 months vs. 66 months). The quality adjusted survival (QAS) of patients who received goserelin was longer (122.5 ± 6.3 vs. 112.2 ± 6.7 months). Total expenses of goserelin were more than cyclophosphamide, methotrexate, 5-fluorouracil (CMF) or 5-fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy regimes, but less than docetaxel, epirubicin (TE) or docetaxel, epirubicin, cyclophosphamide (TEC) regimes. The quality-adjusted life-year was higher in the goserelin group.

Conclusions

Goserelin therapy results in better survival and higher utility-weighted life-years, and is more cost-effective than TC or TEC chemotherapy.
Appendix
Available only for authorised users
Literature
1.
Limonta P, Montagnani MM, Moretti M: LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs. 2001, 10: 709-720. 10.1517/13543784.10.4.709.CrossRefPubMed
2.
Aebi S, Gelber S, Castiglione-Gertsch M, et al: Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet. 2000, 355: 1869-1874. 10.1016/S0140-6736(00)02292-3.CrossRefPubMed
3.
Bernhard J, Zahrieh D, Castiglione-Gertsch M, et al: Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients: the International Breast Cancer Study Group Trial VIII. J Clin Oncol. 2007, 25: 263-270. 10.1200/JCO.2005.04.5393.CrossRefPubMed
4.
Del Mastro L, Catzeddu T, Boni L, et al: Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol. 2006, 17 (1): 74-78.CrossRefPubMed
5.
Recchia F, Sica G, De Filippis S, et al: Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs. 2002, 13 (4): 417-424. 10.1097/00001813-200204000-00011.CrossRefPubMed
6.
de Haes H, Olschewski M, Kaufmann M, et al: Quality of life in goserelin- treated versus cyclophosphamide + methotrexate + fluorouracil treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. J Clin Oncol. 2003, 21: 4510-4516. 10.1200/JCO.2003.11.064.CrossRefPubMed
7.
Kaufmann M, Graf E, Jonat W, et al: Goserelin versus control after adjuvant, risk adapted chemotherapy in premenopausal women with breast cancer GABG trial IV-B-93. J Clin Oncol. 2004, 22 (14 s): 588-(abstract 588)
8.
Jonat W, Kaufmann M, Sauerbrei W, et al: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002, 20 (24): 4628-4635. 10.1200/JCO.2002.05.042.CrossRefPubMed
9.
Hwang JS, Tsauo JY, Wang JD: Estimation of expected quality adjusted survival by cross sectional survey. Stat Med. 1996, 15: 93-102. 10.1002/(SICI)1097-0258(19960115)15:1<93::AID-SIM155>3.0.CO;2-2.CrossRefPubMed
10.
Hwang JS, Wang JD: Monte Carlo estimation of extrapolation of quality-adjusted survival for follow-up studies. Stat Med. 1999, 18: 1627-1640. 10.1002/(SICI)1097-0258(19990715)18:13<1627::AID-SIM159>3.0.CO;2-D.CrossRefPubMed
11.
Hsu C, Wang JD, Hwang JS: Survival-weighted health profile for long-term survivors of acute myelogenous leukemia. Qual Life Res. 2003, 12: 503-517. 10.1023/A:1025043113819.CrossRefPubMed
12.
Chu PC, Wang JD, Hwang JS, Chang YY: Estimation of life expectancy and the expected years of life lost in patients with major cancers: extrapolation of survival curves under high-censored rates. Value Health. 2008, 11: 1102-1109. 10.1111/j.1524-4733.2008.00350.x.CrossRefPubMed
13.
Samant RS, Dunscombe PB, Roberts GH: A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. Urol Oncol. 2003, 21 (3): 171-177. 10.1016/S1078-1439(02)00242-9.CrossRefPubMed
14.
Konski A, Watkins-Bruner D, Brereton H, et al: Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer. 2006, 106 (1): 51-57. 10.1002/cncr.21575.CrossRefPubMed
15.
Zhao H, Kanda K: Testing psychometric properties of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30). J Epidemiol. 2004, 14 (6): 193-203. 10.2188/jea.14.193.CrossRefPubMed
16.
Rashidi AA, Anis AH, Marra CA: Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health Qual Life Outcomes. 2006, 4: 25-34. 10.1186/1477-7525-4-25.CrossRefPubMedPubMedCentral
17.
Fayers P, Aaronson N, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual, EORTC Study Group on Quality of Life:. 1995, Brussels, Belgium
18.
Fang CT, Chang YY, Hsu HM, et al: Life expectancy of patients with newly diagnosed HIV infection in the era of highly active antiretroviral therapy. QJM. 2007, 100: 97-105.CrossRefPubMed
19.
Huang CS, Chang KJ, Shen CY: Breast cancer screening in Taiwan and China. Breast Dis. 2001, 13: 41-48.CrossRefPubMed
20.
Fallowfield L, McGurk R, Dixon M: Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer. Eur J Cancer. 2004, 40: 2403-2410. 10.1016/j.ejca.2004.07.013.CrossRefPubMed
21.
von Minckwitz G, Graf E, Geberth M, et al: Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal women. The GABG trial IV-A-93. J Clin Oncol. 2004, 22 (14 s): 11s:534, (abstract 534).
22.
Jakesz R, Hausmaninger H, Kubista E, et al: Randomization adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and Fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002, 20: 4621-4627. 10.1200/JCO.2002.09.112.CrossRefPubMed
23.
LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, et al: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007, 369 (9574): 1711-1723.CrossRef
24.
Kaufmann M, Jonat W, Blamey R, et al: Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer. 2003, 39 (12): 1711-1717. 10.1016/S0959-8049(03)00392-7.CrossRefPubMed
25.
Norum J: Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer: is it cost-effective?. Acta Oncologica. 2000, 39 (1): 33-39. 10.1080/028418600430941.CrossRefPubMed
26.
Irvin RJ, Kuhn JG: Financial considerations in the use of adjuvant chemotherapy. Adjuvant therapy of breast cancer. Edited by: Henderson IC. 1992, Kluwer Academic Publishers: Norwell, Massachusetts, 207-222.CrossRef
27.
Smith T, Hillner B: The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol. 1993, 11: 771-776.PubMed
28.
Messori A, Becagli P, Trippoli S, et al: Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol. 1996, 51: 111-116. 10.1007/s002280050169.CrossRefPubMed
29.
Wolowacz SE, Cameron DA, Tate HC, et al: Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol. 2008, 26: 925-933. 10.1200/JCO.2006.10.4190.CrossRefPubMed
Metadata
Title
Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
Authors
Tsui Fen Cheng
Jung Der Wang
Wu Ching Uen
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-33

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer

Research article

Regulation of interferon pathway in 2-methoxyestradiol-treated osteosarcoma cells

Study protocol

A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design

Research article

The application of nonsense-mediated mRNA decay inhibition to the identification of breast cancer susceptibility genes

Research article

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

Research article

Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits